Wolverine is a vendor-compounded blend of BPC-157 and TB-500 that users take for tissue healing, injury repair, and inflammation and pain management, and community reports skew strongly positive. The most common regimen is 500 mcg a day, with reported doses ranging from 250 mcg to 2 mg, mostly dosed daily. The blend carries no FDA approval, so all human use is off-label or compounded; injection-site reactions and sleep changes each surface only occasionally in community reports, and other common side effects have not been a consistent theme.
Data last updated
Measured on 4 of 6 axes
Evidence shape
Wolverine currently lacks any published human clinical evidence, meaning there are no registered trials or peer-reviewed data to support its use in humans. Because no clinical research exists, there is no established safety profile or efficacy data for any specific indication. The absence of trial documentation or published results indicates that this peptide remains entirely unstudied in a clinical context.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How Wolverine is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Most community users take Wolverine once a day, typically around 1 mg (range 250 mcg–2 mg); a smaller number dose twice daily at about 500 mcg each, while a few use three‑times‑daily, weekly, or an unstated schedule.